Download PDF
CC BY-NC-ND 4.0 · Avicenna J Med 2022; 12(01): 031-033
DOI: 10.1055/s-0042-1743209
Case Report

A Case of Minimal Change Disease after SARS-CoV-2 Vaccination under the Age of 18

Mohamad Nour Alhosaini
1   Department of Nephrology, American Hospital, Dubai, United Arab Emirates
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Abstract

This is a care report of a 16-year-old-male who developed de novo minimal change disease following the second dose of the Pfizer vaccine. The patient developed sudden onset edema and 10 kg weight gain. He had nephrotic range proteinuria with normal renal function. Kidney biopsy with adequate sample confirmed minimal change disease. The patient improved after 1 week of starting prednisone. This is the first case of minimal change disease after the Pfizer vaccine in the teenager population since expanding the age groups to allow younger subjects to receive the vaccine. Reporting cases at different age groups will help in trying to clarify whether the increasing reports of nephrotic syndrome following the vaccination are accidental or cause–effect relationship.

Keywords

minimal change disease - Pfizer - SARS-COV-2


Publication History

Article published online:
10 March 2022

© 2022. Syrian American Medical Society. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Lebedev L, Sapojnikov M, Wechsler A. et al. Minimal change disease following the Pfizer–BioNTech COVID-19 vaccine. Am J Kidney Dis. 2021; S0272–6386(21)00509–6;
    CrossrefPubMedSearch in Google Scholar
  • 2 D'Agati VD, Kudose S, Bomback AS. et al. Minimal change disease and acute kidney injury following the Pfizer–BioNTech COVID-19 vaccine. Kidney Int. 2021; S0085–2538(21)00493–2;
    CrossrefPubMedSearch in Google Scholar
  • 3 Maas RJ, Gianotten S, van der Meijden WAG. An additional case of minimal change disease following the Pfizer–BioNTech COVID-19 vaccine. Am J Kidney Dis. 2021; 78 (02) 312
    PubMedSearch in Google Scholar
  • 4 Weijers J, Alvarez C, Hermans MMH. Post-vaccinal minimal change disease. Kidney Int 2021; 100 (02) 459-461 (online ahead of print)
    CrossrefPubMedSearch in Google Scholar
  • 5 Kervella D, Jacquemont L, Chapelet-Debout A. et al. Minimal change disease relapse following SARS-CoV-2 mRNA vaccine. Kidney Int. 2021; S0085–2538(21)00478–6;
    CrossrefPubMedSearch in Google Scholar
  • 6 Schwotzer N, Kissling S, Fakhouri F. Letter regarding “Minimal change disease relapse following SARS-CoV-2 mRNA vaccine”. Kidney Int. 2021; S0085–2538(21)00500–7;
    CrossrefPubMedSearch in Google Scholar
  • 7 Komaba H, Wada T, Fukagawa M. Relapse of minimal change disease following the Pfizer–BioNTech COVID-19 vaccine. Am J Kidney Dis. 2021; S0272–6386(21)00627–2;
    CrossrefPubMedSearch in Google Scholar
  • 8 Morlidge C, El-Kateb S, Jeevaratnam P, Thompson B. Relapse of minimal change disease following the AstraZeneca COVID-19 vaccine. Kidney Int 2021; 100 (02) 459
    CrossrefPubMedSearch in Google Scholar
  • 9 Holzworth A, Couchot P, Cruz-Knight W. et al. Minimal change disease following the Moderna mRNA-1273 SARS-CoV-2 vaccine. Kidney Int. 2021; S0085–2538(21)00501–9;
    CrossrefPubMedSearch in Google Scholar
  • 10 Aydın MF, Yıldız A, Oruc A. et al. Relapse of primary membranous nephropathy after inactivated SARS-CoV-2 virus vaccination. Kidney Int. 2021; S0085–2538(21)00494–4;
    CrossrefPubMedSearch in Google Scholar
  • 11 Sahin U, Muik A, Derhovanessian E. et al. COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. Nature 2020; 586 (7830): 594-599
    CrossrefPubMedSearch in Google Scholar
  • 12 Shimoyama H, Nakajima M, Naka H. et al. Up-regulation of interleukin-2 mRNA in children with idiopathic nephrotic syndrome. Pediatr Nephrol 2004; 19 (10) 1115-1121
    CrossrefPubMedSearch in Google Scholar
  • 13 Neuhaus TJ, Wadhwa M, Callard R, Barratt TM. Increased IL-2, IL-4 and interferon-gamma (IFN-gamma) in steroid-sensitive nephrotic syndrome. Clin Exp Immunol 1995; 100 (03) 475-479
    CrossrefPubMedSearch in Google Scholar
  • 14 Kamar N, Abravanel F, Marion O, Couat C, Izopet J, Del Bello A. Three doses of an MRNA COVID-19 vaccine in solid-organ transplant recipients. N Engl J Med 2021; 385 (07) 661-662
    CrossrefPubMedSearch in Google Scholar